Intravitreal Bevacizumab for Foveal Detachment in Idiopathic Perifoveal Telangiectasia

Júnior, Otacílio Oliveira Maia; Bonanomi, Maria Teresa Brizzi Chizzotti; Takahashi, Walter Yukihiko; Nascimento, Vinícius Paganini; Takahashi, Beatriz Sayuri

doi:10.1016/j.ajo.2007.03.059

Cited by 28 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the risk of permanent RPE damage with PDT, coupled with the huge evidence of efficacy of VEGF antagonists in the treatment of choroidal neovascularization in various entities, the anti-VEGF approach is a reasonable treatment alternative for proliferative IJFT IIA, particularly in the presence of retinochoroidal anastomosis. Several case series in the literature investigated bevacizumab or ranibizumab for the treatment of proliferative IJFT IIA but with limited (12 months or less) follow-up 92–99. In a nonrandomized, interventional case series of six eyes with proliferative IJFT IIA that received a single injection of intravitreal bevacizumab (1.25 mg), VA improved two or more lines in five eyes (83%) and remained the same in one eye (17%) at final follow-up (3–6 months).…”

Section: Group Iia: Occult and Nonexudative Idiopathic Juxtafoveolar mentioning

confidence: 99%

Idiopathic juxtafoveolar retinal telangiectasis: A current review

Nowilaty

Al-Shamsi

Al-Khars

2010

Middle East Afr J Ophthalmol

View full text Add to dashboard Cite

Idiopathic juxtafoveolar retinal telangiectasis (IJFT), also known as parafoveal telangiectasis or idiopathic macular telangiectasia, refers to a heterogeneous group of well-recognized clinical entities characterized by telangiectatic alterations of the juxtafoveolar capillary network of one or both eyes, but which differ in appearance, presumed pathogenesis, and management strategies. Classically, three groups of IJFT are identified. Group I is unilateral easily visible telangiectasis occurring predominantly in males, and causing visual loss as a result of macular edema. Group II, the most common, is bilateral occurring in both middle-aged men and women, and presenting with telangiectasis that is more difficult to detect on biomicroscopy, but with characteristic and diagnostic angiographic and optical coherence tomography features. Vision loss is due to retinal atrophy, not exudation, and subretinal neovascularization is common. Group III is very rare characterized predominantly by progressive obliteration of the perifoveal capillary network, occurring usually in association with a medical or neurologic disease. This paper presents a current review of juxtafoveolar retinal telangiectasis, reviewing the classification of these entities and focusing primarily on the two most common types encountered in clinical practice, i.e., groups I and II, describing their clinical features, histopathology, natural history, complications, latest results from imaging modalities and functional studies, differential diagnosis, and treatment modalities.

show abstract

Section: Group Iia: Occult and Nonexudative Idiopathic Juxtafoveolar mentioning

confidence: 99%

Idiopathic juxtafoveolar retinal telangiectasis: A current review

Nowilaty

Al-Shamsi

Al-Khars

2010

Middle East Afr J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…12,15,16,17,18,19,20,21,22 In some of these studies, however, the leakage on FA was reported to return to baseline levels during periods without injections. 15,17,20,22 Similarly, though decreases in macular thickness measured by OCT may be detected initially, 12,16,17,18,19,20,21,22,24 studies with long-term follow-up after the final injection reported that OCT findings also returned to baseline. 17,18,20,22 Besides these studies, there are others in which no substantial changes in OCT findings were observed.…”

Section: Discussionmentioning

confidence: 98%

“…In recent years, intravitreal anti-vascular endothelial growth factor (VEGF) injection has been administered to proliferative and nonproliferative patient groups in a variety of studies. 12,13,14,15,16,17,18,19,20,21,22,23,24 Although the results of these studies differ, some patients reportedly benefited from intravitreal anti-VEGF injections.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

Aydoğan

Erdoğan

Ünlü

et al. 2016

tjo

View full text Add to dashboard Cite

Objectives: To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT).Materials and Methods: Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were included in this study. All the patients had an ophthalmological examination including best corrected visual acuity (BCVA), dilated fundus examination, spectral domain optical coherence tomography (OCT) and fluorescein angiography. Intravitreal bevacizumab injection was planned for patients who had macular edema and/or decreased visual acuity at baseline. Patients were examined 1 week and 1 month after the intravitreal injection. Intravitreal injection was repeated in patients whose visual acuity decreased and/or whose macular edema persisted or increased. Changes in BCVA, central macular thickness (CMT) and central macular volume from baseline at 1 month after the first injection and at final examination were evaluated.Results: Average age of the patients (4 female and 1 male) was 62±11.8 years. Average follow-up period was 26±11 months. Patients received an average of 2.3 (range 1-4) injections during follow-up. Average Snellen BCVA of the patients was 0.48±0.29. BCVA increased at final examination compared to baseline in all of the patients. The difference between baseline and final visual acuities was significant (p<0.05). The patients’ average CMT was 328±139 µm at baseline and decreased by a mean of 85±153 µm at 1 month after the first injection and 65±142 µm at final examination, but the changes were not significant. CMT decreased at final examination compared to baseline in four patients and increased in both eyes of one patient.Conclusion: Intravitreal bevacizumab injection is a preferable treatment method in regard to both visual acuity and OCT findings.

show abstract

“…Several case series in the literature investigated the effects of bevacizumab or ranibizumab but with limited (12 months or less) follow-up [80,81,82,83,84,85,86,87]. A single injection of intravitreal bevacizumab (1.25 mg) seems to be effective to improve VA and to decrease mean central foveal thickness.…”

Section: Retinal Telangiectasiasmentioning

confidence: 99%

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

et al. 2012

View full text Add to dashboard Cite

Primitive retinal vascular abnormalities are benign conditions of the retinal circulation that comprise vascular tumors and telangiectasias. The principal vascular tumors of the retina include retinal capillary hemangioma, cavernous hemangioma of the retina, racemose hemangiomatosis of the retina and retinal vasoproliferative tumor, while primary retinal telangiectasias include Coats’ disease, Leber’s miliary aneurysms and idiopathic juxtafoveal telangiectasias. In most cases, these alterations result in significant visual impairment due to exudation determined by the structural abnormalities of the retinal vasculature. The aim of this review is to assess the different clinical and diagnostic features of the single pathological entities and to discuss the available treatment modalities including the onset of intravitreal antivascular endothelial growth factor therapy.

show abstract

Intravitreal Bevacizumab for Foveal Detachment in Idiopathic Perifoveal Telangiectasia

Cited by 28 publications

References 7 publications

Idiopathic juxtafoveolar retinal telangiectasis: A current review

Idiopathic juxtafoveolar retinal telangiectasis: A current review

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

Contact Info

Product

Resources

About